Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies Into Clinical Practice
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 15, 2022 Expiration: September 14, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Dova Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Sanofi Genzyme
David J. Kuter, MD, DPhil
Program Director
Catherine M. Broome, MD
Cindy Neunert, MD, MSCS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify newly diagnosed patients with ITP who would benefit from intensified therapy to improve remission rates
  • Select optimal second or subsequent lines of therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Plan therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, pregnant women, and those with COVID-19, with chronic liver disease, undergoing a planned medical procedure, or receiving chemotherapy
  • Evaluate new clinical trial data and the clinical practice implications of novel targeted therapies in patients with immune thrombocytopenia
  • Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter, MD, DPhil: consultant/advisor/speaker: Actelion, Agios, Alnylam, Amgen, Argenx, BioCryst, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Pfizer, Principis, Protalex, Protalix, Rigel, Sanofi Genzyme, Shionogi, Shire, Takeda, UCB, Zafgen; researcher: Actelion, Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalix, Rigel, Takeda, UCB.

Faculty

Catherine M. Broome, MD

Associate Professor of Medicine
Lombardi Cancer Center
MedStar Georgetown University
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Incyte, Sanofi; researcher: Argenx.
Cindy Neunert, MD, MSCS

Associate Professor
Pediatrics, Hematology/Oncology, Stem Cell Transplant
Columbia University Irving Medical Center
New York, New York

Cindy Neunert, MD, MSCS: consultant/advisor/speaker: Janssen, Sobi; researcher: Novartis.

Staff

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists and other healthcare professionals who care for patients with ITP.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with immune thrombocytopenia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 15, 2022, through September 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies Into Clinical Practice
  • CME

Loading...
Watch this on-demand webcast of a live symposium at THSNA 2022 featuring expert discussion on the management of patients with ITP.
David J. Kuter, MD, DPhil
Program Director
Catherine M. Broome, MD
Cindy Neunert, MD, MSCS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 15, 2022 Expiration: September 14, 2023

Related Content

Enter characteristics of your patient with immune thrombocytopenia (ITP) into this online tool to see recommendations from 5 experts

Hanny Al-Samkari, MD Catherine M. Broome, MD Sandhya Ramanathan Panch, MD, MPH person default Kristin Ammon Shimano, MD Released: October 26, 2022

Dr Hanny Al-Samkari of Harvard Medical School and Massachusetts General Hospital reviews current and investigational treatments for ITP, from Clinical Care Options (CCO)

Hanny Al-Samkari, MD Released: October 18, 2022

Experts present emerging strategies for treatment of hemophilia A and B with the goal of restoring hemostatic balance, from Clinical Care Options (CCO)

Guy A. Young, MD
Program Director
Glaivy Batsuli, MD Allison Wheeler, MD, MSCI
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 26, 2022 Expired: September 25, 2023

Downloadable slideset on the key teaching points and considerations in the management of ITP, from Clinical Care Options (CCO)

Catherine M. Broome, MD David J. Kuter, MD, DPhil Cindy Neunert, MD, MSCS Released: August 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Dova Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings